Printer Friendly

ATRIX LABORATORIES ANNOUNCES REVISION TO COLGATE CONTRACT

 FORT COLLINS, Colo., Feb. 1 /PRNewswire/ -- Atrix Laboratories, Inc. (NASDAQ-NMS: ATRX), announced today that Colgate-Palmolive Co. (NYSE: CL) has given notice that it is terminating the agreement regarding the Atrisorb(TM) Guided Tissue Regeneration Product and has waived its marketing rights to the product. Colgate will remain Atrix's marketing partner for its sanguinarine based Pario Product which will be marketed to dental professionals for the treatment of periodontal disease after receiving FDA approval.
 Colgate said that the modification in the method of application of the Atrisorb product no longer fits with Colgate's marketing criteria. However, Atrix believes that the application method will be acceptable to dental professionals and that the characteristics of the Atrisorb product will make it superior to products currently in the marketplace. The Atrisorb product is a medical device designed to optimize tissue regeneration following periodontal flap surgery.
 Dr. G. Lee Southard, president and CEO, stated: "As per the agreement, each party committed to invest up to $1 million. The $2 million invested in the Atrisorb product to date has placed us in human clinical trials. Based on results to date, we anticipate that Atrix will be able to enter into a new marketing agreement with another party to complete the development of the Atrisorb Guided Tissue Regeneration Product."
 Additionally, Colgate's rights to convert its $4 million note into Atrix common stock expired on Jan. 1, 1993. Because interest began accruing at 12 percent on Jan. 15, Atrix has prepaid the note.
 Dr. Southard concluded by saying that Atrix continues to develop the Pario Product with sanguinarine and doxycycline for the treatment of periodontal disease. The products are currently in human clinical trials and the trials are proceeding on schedule.
 -0- 2/1/93
 /CONTACT: Dr. G. Lee Southard, president and CEO of Atrix, 303-482-5868; or Susan Sherman of Cameron Associates, 212-644-9560, for Atrix/
 (ATRX CL)


CO: Atrix Laboratories, Inc.; Colgate-Palmolive Co. ST: Colorado IN: HEA SU: CON

GK-OS -- NY030 -- 1330 02/01/93 11:29 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 1, 1993
Words:330
Previous Article:SUNDSTRAND REVIEWS 1992 RESULTS AND ACTIVITIES
Next Article:PLAYBOY ENTERPRISES REPORTS IMPROVEDRESULTS FOR FISCAL 1993 SECOND QUARTER
Topics:


Related Articles
ATRIX LABORATORIES REPORTS SECOND QUARTER AND SIX MONTH RESULTS; ANNOUNCES ACQUISITION OF SRI TECHNOLOGY
ATRIX LABORATORIES COMMENCES CLINICAL STUDIES ON PERIODONTAL PRODUCTS
ATRIX LABORATORIES REPORTS RESULTS OF LIMITED PARTNERS MEETING
ATRIX LABORATORIES BROADENS RESEARCH IN DRUG DELIVERY ARENA
ATRIX LABORATORIES AND COLGATE PALMOLIVE TO END MARKETING AGREEMENT
ATRIX PROPOSES STOCK EXCHANGE WITH VIPONT ROYALTY INCOME FUNDS, LTD.
Block Drug Company And Atrix Laboratories Sign Corporate Alliance Agreement
Atrix Laboratories Reports 1997 First Quarter Results
Block Drug Corporation to Market Atridox(TM) Periodontal Therapy in Canada
Atrix Laboratories Reports 1997 Third Quarter and Nine Month Financial Results

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters